Pregabalin as adjunctive therapy in adult and pediatric patients with generalized tonic‐clonic seizures: A randomized, placebo‐controlled trial

Driscoll, Joseph R.; Almas, Mary; Gregorian, Gabriela; Kyrychenko, A. H.; Makedonska, Iryna; Liu, Jing; Patrick, Jeffrey; Scavone, Joseph M.; Antinew, Jeremias

doi:10.1002/epi4.12492

Cited by 5 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9,10 The GTCS is more pervasive in elders, and can be caused by a plethora of reasons, including hypoxia, ischemia, low-grade glioma, cortical dysplasia, encephalitis, trauma, and cerebrovascular diseases. [11][12][13] It is a severe neurological emergency and is often accompanied by altered consciousness or complete loss of consciousness. Lack of timely control of the seizure may lead to life-threatening respiratory depression, joint muscle injury, and brain edema.…”

Section: Discussionmentioning

confidence: 99%

Changes in routine blood parameters of patients with generalized tonic clonic seizure: a retrospective study

Huang

Yang

Miao

et al. 2023

NSJ

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Changes in routine blood parameters of patients with generalized tonic clonic seizure: a retrospective study

Huang

Yang

Miao

et al. 2023

NSJ

View full text Add to dashboard Cite

show abstract

“…In this aspect, anti-seizure efficacy for focal and focal-onset seizures has been well-documented with ≥50% seizure reduction in >40% of human patients ( 18 , 49 , 50 , 52 ). Recent investigations in children and adults failed to demonstrate a significant effect of PGB on generalized-onset tonic–clonic seizures compared to placebo ( 53 ). In dogs with idiopathic epilepsy, the most frequent seizure type is “focal epileptic seizure” evolving into generalized epileptic seizures ( 27 ), which is the equivalent of “focal to bilateral tonic–clonic seizure” in humans ( 54 ).…”

Section: Discussionmentioning

confidence: 99%

Pregabalin Add-On vs. Dose Increase in Levetiracetam Add-On Treatment: A Real-Life Trial in Dogs With Drug-Resistant Epilepsy

Kriechbaumer

Jurina²,

Wielaender

et al. 2022

Front. Vet. Sci.

View full text Add to dashboard Cite

Epilepsy is a common neurological disorder affecting 0.6–0.75% of dogs in veterinary practice. Treatment is frequently complicated by the occurrence of drug-resistant epilepsy and cluster seizures in dogs with idiopathic epilepsy. Only few studies are available to guide treatment choices beyond licensed veterinary drugs. The aim of the study was to compare antiseizure efficacy and tolerability of two add-on treatment strategies in dogs with drug-resistant idiopathic epilepsy. The study design was a prospective, open-label, non-blinded, comparative treatment trial. Treatment success was defined as a 3-fold extension of the longest baseline interseizure interval and to a minimum of 3 months. To avoid prolonged adherence to a presumably ineffective treatment strategy, dog owners could leave the study after the third day with generalized seizures if the interseizure interval failed to show a relevant increase. Twenty-six dogs (mean age 5.5 years, mean seizure frequency 4/month) with drug-resistant idiopathic epilepsy and a history of cluster seizures were included. Dogs received either add-on treatment with pregabalin (PGB) 4 mg/kg twice daily (14 dogs) or a dose increase in levetiracetam (LEV) add-on treatment (12 dogs). Thirteen dogs in the PGB group had drug levels within the therapeutic range for humans. Two dogs in the PGB group (14.3%; 2/14) and one dog in the LEV group (8.3%; 1/12) achieved treatment success with long seizure-free intervals from 122 to 219 days but then relapsed to their early seizure frequency 10 months after the study inclusion. The overall low success rates with both treatment strategies likely reflect a real-life situation in canine drug-resistant idiopathic epilepsy in everyday veterinary practice. These results delineate the need for research on better pharmacologic and non-pharmacologic treatment strategies in dogs with drug-resistant epilepsy.

show abstract

“…Group P was given oral pregabalin 5 mg/kg 60 minutes before induction, while group C was given a placebo. [ 5 ] The Visual Analog Scale for Anxiety (VAS-A) and the Ramsay Sedation Scale (RSS) were practiced with all cases before induction. Side effects recorded (nausea, vomiting, vertigo and dizziness) were recorded as baseline immediately before induction (1 h post-dose) and after recovery (2 h, 3 h, 4 h, and 6 h post-dose).…”

Section: Aterials and M Ethodsmentioning

confidence: 99%

Efficacy and Safety of Single-Dose Pregabalin in Preoperative Pediatric Sedation

Mahdy,

Saad,

Gad

et al. 2024

Journal of Pharmacy and Bioallied Sciences

View full text Add to dashboard Cite

Introduction: This study aimed to investigate the anxiolytic and sedative effects of a single oral dose of 5 mg/kg pregabalin in pediatric patients undergoing elective surgery. It also assessed potential adverse effects and its impact on bispectral index (BIS) responses Materials and Methods: This prospective randomized clinical trial enrolled 60 pediatric patients undergoing minor elective surgery. Patients were randomly assigned to receive either oral pregabalin (5 mg/kg) or a placebo one hour before induction of anesthesia. Anxiety levels were assessed using the Visual Analog Scale for Anxiety (VAS-A), and sedation levels were evaluated using the Ramsay Sedation Scale (RSS). Results: Pregabalin premedication significantly reduced preoperative anxiety, as indicated by lower VAS-A scores compared to the control group. Sedation levels, measured using the RSS, were significantly higher in the pregabalin group at various time points post-dose. During intubation, skin incision, and recovery, BIS responses were significantly lower in the pregabalin group Conclusion: The use of single-dose pregabalin preoperatively in children recorded a significant decrease in anxiety and achieved a state of sedation without an increase in adverse effects.

show abstract

Pregabalin as adjunctive therapy in adult and pediatric patients with generalized tonic‐clonic seizures: A randomized, placebo‐controlled trial

Abstract: This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Cited by 5 publications

References 30 publications

Changes in routine blood parameters of patients with generalized tonic clonic seizure: a retrospective study

Changes in routine blood parameters of patients with generalized tonic clonic seizure: a retrospective study

Pregabalin Add-On vs. Dose Increase in Levetiracetam Add-On Treatment: A Real-Life Trial in Dogs With Drug-Resistant Epilepsy

Efficacy and Safety of Single-Dose Pregabalin in Preoperative Pediatric Sedation

Contact Info

Product

Resources

About